Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IONIS-FXIRx in patients with end-stage renal disease on hemodialysis
2017-002165-21Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Aug 2017
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fesomersen in thrombosis (4 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Major bleeding and clinically relevant non-major bleeding, Factor XI activity reduction and 2 more. Started Aug 2017; status: completed.
02
Drugs
fesomersen
03
Conditions
thrombosis
Beyond the preview
Go deeper on 2017-002165-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002165-21.